Clinical trial · Interventional
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
A Pilot Study of Radiolabeled Indium-111 and Yttrium-90 Ibritumomab Tiuxetan in Primary CNS Lymphoma
NCT00082836CI-TRIAL-00008980completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies, such as rituximab and yttrium Y 90 ibritumomab tiuxetan, can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This clinical trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with recurrent primary CNS lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rituximab | Biological | Rituximab | ALIAS |
| yttrium Y 90 ibritumomab tiuxetan | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Dosimetry at 1, 24, and 48 hours
Secondary outcomes (2)
- measure
- Safety by NCI common toxicty criteria
- measure
- Radiographic response at 1 and 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed non-Hodgkin's lymphoma (NHL)
* Recurrent disease
* Isolated CNS relapse of systemic NHL allowed
* Primary CNS lymphoma
* Measurable gadolinium-enhancing lesion on MRI of the brain
* No impaired bone marrow reserve
* No hypocellular bone marrow
* No marked reduction in bone marrow precursors of one or more cell lines (granulocytic, megakaryocytic, erythroid)
* No pleural effusion
* No chronic lymphocytic leukemia
* No AIDS-related lymphoma
PATIENT CHARACTERISTICS:
Age
* Adult
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Platelet count \> 100,000/mm\^3
* Absolute neutrophil count ≥ 1,500/mm\^3
Hepatic
* Bilirubin ≤ 2.0 mg/dL
Renal
* Creatinine ≤ 2.0 mg/dL
Other
* HIV negative
* No serious nonmalignant disease that would preclude study participation
* No infection
* No anti-murine antibody reactivity\*
* No human anti-mouse antibodies
* Not pregnant
* Negative pregnancy test NOTE: \*Results must be available prior to study entry for patients who received prior murine antibodies or proteins, other than rituximab
PRIOR CONCURRENT THERAPY:
Biologic therapy
* See Radiotherapy
* No prior stem cell transplantation
* No prior myeloablative therapies with autologous bone marrow transplantation or peripheral blood stem cell rescue
* No prior failed stem cell collection
* More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
Chemotherapy
* No more than 1 prior chemotherapy regimen
Endocrine therapy
* Not specified
Radiotherapy
* No prior radioimmunotherapy
* No prior whole-brain radiotherapy
* No prior external beam radiotherapy (involved field or regional) to \> 25% of active bone marrow
Surgery
* More than 4 weeks since prior major surgery except diagnostic surgeryReferences
Publications (0)
Data not yet available
No reference posted for this study.